PCI Biotech: Invitation to first-half year 2022 results presentation
Oslo, Norway, 26 August 2022 - PCI Biotech (OSE: PCIB) invites to an online presentation of the company's first-half year 2022 interim report on Wednesday 31 August 2022, 08:30am – 09:30am CEST (local time).
The presentation will be held as a live webcast and can be accessed through www.pcibiotech.com. There will be a Q&A session at the end of the presentation and it will be possible to post written questions through the webcast console or through a teleconference facilitated for attendees intending to ask questions verbally during the Q&A session.
PCI Biotech’s first-half year 2022 interim report will be released on 31 August 2022 at 07.00 CEST. The interim report and presentation will be made available on www.newsweb.no and on the company's webpage, www.pcibiotech.com.
For further information, please contact:
Ronny Skuggedal, Interim CEO / CFO
Email: rs@pcibiotech.no
Mobile: +47 9400 5757
About PCI Biotech
PCI Biotech is a biopharmaceutical company focusing on development and commercialisation of novel therapies for the treatment of cancer through its innovative photochemical internalisation (PCI) technology platform. PCI induces triggered endosomal release that is used to unlock the true potential of therapeutic modalities.
The fimaVacc programme aims to enhance immunotherapy in cancer, by triggered endosomal release of antigens or nucleic acids encoding antigens, or immunostimulatory factors. In the fimaNAc programme endosomal release is utilised to provide intracellular delivery of nucleic acids, such as mRNA and RNAi therapeutics, thereby addressing one of the major bottlenecks facing this emerging and promising field.
For further information, please visit: www.pcibiotech.com
Contact information: PCI Biotech Holding ASA, Ullernchausséen 64, N-0379 Oslo
Forward-looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
DECISIONS OF DIGITALIST GROUP PLC’S ANNUAL GENERAL MEETING 25 APRIL 2024 AND THE ORGANIZING MEETING OF THE BOARD OF DIRECTORS25.4.2024 19:00:00 CEST | Press release
DECISIONS OF DIGITALIST GROUP PLC’S ANNUAL GENERAL MEETING 25 APRIL 2024 AND THE ORGANIZING MEETING OF THE BOARD OF DIRECTORS Digitalist Group Oyj Stock Exchange Release 25 April 2024 at 20:00 DECISIONS OF DIGITALIST GROUP PLC’S ANNUAL GENERAL MEETING 25 APRIL 2024 Adoption of the financial statements The Annual General Meeting of Digitalist Group Plc (the “Company”) adopted the Company’s financial statements and consolidated financial statements for the financial period 1 January -31 December 2023. Resolution on the use of the loss shown on the balance sheet and on the distribution of assets The Annual General Meeting resolved that the loss EUR 4,575,895.22 indicated by the financial statements for 2023 be recorded in the Company’s profit and loss account, and that no dividend be paid to shareholders for the financial period 2023. Resolution on the discharge of the members of the Board of Directors and the CEO from liability for the financial period 1 January 2023 to 31 December 2023
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC25.4.2024 19:00:00 CEST | Press release
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – April 25, 2024 – 07:00 PM CET (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on April 25, 2024, from Atlas Special Opportunities, LLC indicating that as of April 19, 2024, it held 380,755,774 shares of the then outstanding 9,014,821,287 shares, and therefore crossed below the threshold (5%) by virtue of the sale of voting securities. See Annex 1. About Oxurion Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium. More information is available at www.oxurion.com. Important information about forward-looking statements Certain statements in this press release may
Heineken Holding N.V. Annual General Meeting of Shareholders adopts all proposals25.4.2024 18:31:00 CEST | Press release
Amsterdam, 25 April 2024 - Heineken Holding N.V. announced today that its Annual General Meeting of Shareholders (AGM) has adopted all proposals on the agenda of the AGM. The most important resolutions and announcements are listed below. Dividend The Board of Directors announced the distribution of a dividend for the year 2023 of EUR 1.73 per share. As an interim dividend of EUR 0.69 was paid on 10 August 2023, the final dividend of EUR 1.04 per share will be made payable on 7 May 2024. Heineken Holding N.V. shares will be quoted ex-dividend on 29 April 2024. Reappointment of Mr J.F.M.L. van Boxmeer as non-executive member of the Board of Directors The AGM reappointed Mr J.F.M.L. van Boxmeer as non-executive member of the Board of Directors for a four-year term. Appointment of External Auditor The AGM appointed KPMG Accountants N.V. as external auditor for the financial year 2025. The voting results per agenda item of the AGM of Heineken Holding N.V. of 25 April 2024 can be found on th
Heineken N.V. Annual General Meeting adopts all proposals25.4.2024 18:30:00 CEST | Press release
Amsterdam, 25 April 2024 - Heineken N.V. (HEINEKEN) announced today that its Annual General Meeting of Shareholders (AGM) has adopted all proposals on the agenda of the AGM. The most important resolutions are listed below. Re-appointment of Executive Board Member The AGM re-appointed Dolf van den Brink as member of the Executive Board for a period of four years, until the end of the AGM to be held in 2028. Dividend The AGM adopted the dividend proposal for the year 2023 of EUR 1.73 per share. As an interim dividend of EUR 0.69 was paid on 10 August 2023, the final dividend of EUR 1.04 per share will be made payable on 7 May 2024. Heineken N.V. shares will be quoted ex-dividend on 29 April 2024. Re-appointment of Supervisory Board Member The AGM re-appointed Jean-Marc Huët as member of the Supervisory Board for a two-year term. Re-appointment of Supervisory Board Member The AGM re-appointed Pamela Mars Wright as member of the Supervisory Board for a two-year term. Appointment of Supervi
Havila Kystruten AS: Integrated Annual Report for 202325.4.2024 18:04:39 CEST | Press release
The board of directors of Havila Kystruten AS has today approved the financial statements and annual report for 2023, which integrates financial and sustainability reporting. The report is attached in PDF format along with a visual presentation summarizing the year and highlighting the company's fundamental focus on the environment and sustainability. The annual financial statements have been adjusted compared to the preliminary and unaudited result for 2023, which was presented on February 28, 2024. There has been a write-down of the inventory value by NOK 11.2 million, with corresponding effects on the income statement and balance sheet. Further information is available in note 15 of the consolidated financial statements. Contacts: Chief Executive Officer Bent Martini, +47 905 99 650 Chief Financial Officer Aleksander Røynesdal, +47 413 18 114 Attachments HKY_Integrated Annual Report 2023HKY_Integrated Annual Report Presentation 2023HKY_Integrert arsrapport 2023